Related Experiment Video
Updated: Jun 18, 2026
09:33
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Peripheral T-cell lymphoma gene expression profiling and potential therapeutic exploitations.
Régis Costello1, Carole Sanchez, Thérèse Le Treut
1Department of Haematology, Faculté de Médecine de Marseille, Université de la Méditerranée Aix-Marseille 2, Marseille, France. regis.costello@free.fr
British Journal of Haematology
|November 17, 2009
Summary
Molecular profiling advances the classification and treatment of peripheral T-cell lymphomas. Gene expression analysis reveals distinct biological insights for various subtypes, improving diagnostic accuracy and therapeutic strategies.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Peripheral T-cell lymphomas (PTCLs) are a diverse group with complex diagnosis, treatment, and prognosis.
- Traditional methods like cytology and immunochemistry are being enhanced by novel molecular techniques.
- Understanding the molecular underpinnings of PTCLs is crucial for refining classification and treatment.
Purpose of the Study:
- To explore the utility of molecular profiling, particularly gene expression profiling, in understanding the biology and improving the management of PTCLs.
- To identify distinct molecular signatures associated with specific PTCL subtypes and their clinical implications.
- To investigate potential therapeutic targets based on molecular insights.
Main Methods:
- Gene expression profiling was employed across various PTCL subtypes, including anaplastic large cell lymphoma (ALCL), angioblastic T-cell lymphoma, PTCL-NOS, and primary cutaneous T-cell lymphomas.
- Analysis focused on identifying gene expression signatures, molecular pathways, and cellular origins.
- Correlations were drawn between molecular profiles and clinical parameters, including prognosis and treatment response.
Main Results:
- Specific molecular signatures were identified for ALK-positive ALCL, linked to T-cell receptor signaling and STAT3.
- Gene expression profiling differentiated angioblastic T-cell lymphoma, suggesting follicular helper T cells as the normal counterpart and implicating VEGF.
- For PTCL-NOS, profiling identified activated T-lymphocytes as the normal counterpart, delineated prognostic groups, and suggested targeting NF-κB and PDGFR-α.
- Primary cutaneous T-cell lymphomas showed the importance of methylation patterns and JUNB/AP-1, leading to a predictive model for interferon-alpha response.
Conclusions:
- Gene expression profiling is transforming the pathological classification of T-cell lymphomas.
- Molecular insights are refining prognostic assessments and guiding therapeutic strategies for PTCLs.
- This approach holds significant promise for personalized medicine in T-cell lymphoma management.
